Improving Pain Therapeutics

Applying unique technologies to prolong and enhance efficacy, reduce adverse effects and increase patient’s comfort.

We are a clinical stage specialty pharmaceutical company
focused on the reformulation of established therapeutics

Our proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates very often administered post surgically.

PRF - 110

Viscous clear oil-based solution that is instilled directly into the surgical wound

Providing localized and extended post-operative analgesia. Its physical characteristics and composition are key to it being well-tolerated and its ease of use.

Market

The currently marketed non-opiate extended relief post-surgical topical products are based on a complicated formulation with either liposomes or an artificial polymer, and contain bupivacaine.

investors relation & media

Nasdaq: PRFX

0.50

CHANGE: 9.63%

DAILY VOLUME: 12,021

LAST UPDATE: 06-09-2023 23:59

Send us a Message

this site made by